Floatz logo

Recombinant Human Gm-Csf

Lung Cancer Metastatic

The First Affiliated Hospital of Xiamen UniversityPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Lung Cancer Metastatic cohort.

Asset / SponsorPhaseRating
Rhgm-Csf
Peking University Cancer Hospital & Institute
Phase 2B
Thymosin Alpha 1
The First Affiliated Hospital of Xiamen University
Phase 2CCC
Dabrafenib
Sun Yat-sen University
Phase 2CCC
Evolocumab
Eziafa Oduah, MD, PhD, MPH
Phase 2CCC
Capmatinib
SWOG Cancer Research Network
Phase 2CCC

View all 9 →

Same molecule, other indications

Recombinant Human Gm-Csf is also rated in:

prostate neoplasmDormant
CC
Indicative ·
46 / 100
View asset →
plasma cell myelomaDormant
CC
Indicative ·
42 / 100
View asset →
metastatic malignant neoplasmDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →